FDA
-
-
-
-
-
-
-
FDA grants priority review to J&J cancer drug for head and neck tumors
-
-
-
-
-
-
-
FDA clears Johnson & Johnson dual-energy cardiac ablation catheter
-
-
-
-
-
-
-
Johnson & Johnson expands US availability of TECNIS PureSee IOL
-
-
-
-
-
-
-
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
-
-
-
-
-
-
-
Johnson & Johnson TECVAYLI shows survival benefits in myeloma study
-
-
-
-
-
-
-
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
-
-
-
-
-
-
-
Johnson & Johnson presents CAPLYTA analysis for depression treatment
-
329,330 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

